At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
AZD4901 (oral) +1 moredrug
Likely dose
AZD4901 (oral) 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females With Polycystic Ovary Syndrome
In Brief
A Phase 2 clinical trial evaluating AZD4901 (oral) and Placebo to match AZD4901 for Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder. Completed, enrolled 67 participants across 7 sites in 3 countries.
Detailed Summary
To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedJun 2013
Primary CompletionJul 2014
TodayJul 2026
First PostedJun 7, 2013
Enrollment StartJun 1, 2013
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.1 years ago
Interventions
AZD4901 (oral)drug
Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Placebo to match AZD4901drug
Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo